EYDENZELT
Details
- Status
- Prescription
- First Approved
- 2025-10-02
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
EYDENZELT Approval History
What EYDENZELT Treats
5 indicationsEYDENZELT is approved for 5 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Neovascular Age-Related Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Diabetic Retinopathy
EYDENZELT Target & Pathway
ProTarget
A signaling protein that stimulates the formation of new blood vessels (angiogenesis). Tumors need blood supply to grow, so they secrete VEGF to create new vessels. Blocking VEGF starves tumors of oxygen and nutrients, inhibiting their growth.
Pathway Context
VEGF binds to VEGFR on blood vessel cells to stimulate new vessel formation
Receptors on blood vessel cells that respond to VEGF signals to form new blood vessels. Cancer cells exploit this pathway to ensure blood supply for tumor growth. Blocking VEGFRs prevents tumor angiogenesis and limits cancer progression.
EYDENZELT is a lower-cost alternative to Eylea with no clinically meaningful differences. Requires prescriber approval to substitute.
EYDENZELT Competitors
Pro4 other drugs also target PlGF. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (PlGF). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to EYDENZELT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EYDENZELT FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.